Enhertu 100mg Injection contains the active ingredient Trastuzumab deruxtecan, a targeted therapy used to treat specific types of breast and stomach cancers. It works by binding to HER2-positive cancer cells and delivering a cytotoxic agent that targets and kills these cells. Enhertu is specifically used for adult patients with HER2-positive metastatic breast cancer or HER2-positive gastric cancer, and it is not recommended for individuals under 18 years of age.

Before starting treatment, it is crucial to inform your doctor about any existing medical conditions, particularly lung, liver, or kidney issues, to ensure the medication is safe and appropriate for your treatment. Enhertu uses vary depending on the patient's condition and the progression of the disease, with treatment regimens tailored to individual needs. 

Common side effects of Enhertu Injection are cough, trouble breathing or shortness of breath, fever, new or worsening breathing symptoms (e.g., chest tightness, wheezing), and low white blood cell count (neutropenia). Regular monitoring is essential during treatment to manage potential side effects and optimise therapeutic outcomes.

Treats HER2-positive breast cancer that is metastatic or unresectable for patients who have had prior anti-HER2 treatments.

Effective for HER2-low metastatic breast cancer after prior chemotherapy.

Treats HER2-mutated non-small cell lung cancer (NSCLC) that is metastatic or unresectable following prior treatment.

Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after prior trastuzumab-based therapy.

For HER2-positive (IHC 3+) metastatic solid tumors when no other satisfactory treatments are available.

Enhertu 100mg Injection works in a targeted way to treat certain cancer cells. It is made up of two main parts:

1. Monoclonal Antibody: This part of the medication specifically attaches to cancer cells that have the HER2 protein on their surface. These are known as HER2-positive cancer cells, which are common in some breast and stomach cancers.

2. DXd (Drug Conjugate): This is the other active component of Enhertu 100 mg Injection. DXd is a powerful substance that can kill cancer cells.

Enhertu 100 mg Injection finds and attaches to HER2-positive cancer cells. Once attached, it delivers the DXd directly into these cancer cells. The DXd then works to kill these cells from the inside. This targeted approach helps attack the cancer cells while sparing many healthy cells in the body.

Enhertu 100mg Injection is administered through an intravenous (IV) infusion by a healthcare provider every three weeks. Before each treatment, you may receive medication to prevent nausea and vomiting. If you have an infusion-related reaction, the infusion may be slowed, paused, or permanently stopped for severe reactions. If you miss a dose, it's important to contact your healthcare provider immediately to reschedule. The number of treatments will depend on your healthcare provider's assessment.

Severe allergic reactions (rashes, itching, difficulty in breathing, fever)

Nausea (feeling sick), vomiting

Tiredness

Decreased appetite

Blood tests showing decreased red or white blood cells or platelets

Hair loss

Diarrhoea

Constipation

Blood tests showing increased levels of the liver enzymes such as transaminases

Pain in muscles and bones

Weight loss

Fever

Abdominal (belly) pain

Infections of the nose and throat, including flu-like symptoms

Headache

Blisters in or around your mouth

Cough

Blood tests showing low blood potassium levels

Indigestion

Breathing difficulties

Swelling of ankles and feet

Nosebleed

Altered/bad taste in the mouth

Infection of the lungs

Inform your physician about all the prescribed medicine, over-the-counter medications, nutritional or vitamin supplements, and herbal supplements you have taken before. Certain medications may interact with Enhertu 100mg Injection and can cause undesirable side effects.

Store in the refrigerator at a temperature between 2°C to 8°C.

Do not freeze.

It should be kept away from children and pets.

If you are taking Enhertu 100mg Injection, it is crucial to regularly monitor your lung and liver functions with your doctor due to potential side effects. Both women and men should use effective contraception during treatment. Women should continue using birth control for at least seven months after the final dose of Enhertu 100mg Injection, while men should do so for four months after completing treatment to avoid risks to their partners who may become pregnant. It's essential to consult with your doctor about the best contraceptive methods and inform them before you decide to stop using contraception. Additionally, male patients should be aware that Enhertu 100mg Injection may impact fertility, so it is advisable to avoid fathering a child for four months after treatment and discuss sperm preservation options with your doctor before starting the medication.